Physician profile
Dilip Patel
NPI 1568567097
$340.29
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $89.42 · 2021: $47.33 · 2022: $14.78.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.36 | 2020-2022 | |
| Pfizer INC. | $58.47 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $42.20 | 2019 | |
| Glaxosmithkline, LLC. | $38.15 | 2019 | |
| Merck Sharp & Dohme LLC | $34.35 | 2019-2020 | |
| Philips North America LLC | $26.84 | 2019 | |
| Mannkind Corporation | $25.08 | 2019-2020 | |
| Amarin Pharma, INC. | $22.39 | 2019 | |
| Melinta Therapeutics, LLC | $18.37 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $15.08 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dilip Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.